NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc., a biopharmaceutical company focused on delivering an innovative gamma-delta (??) T cell immunotherapy for the treatment of cancers, today announced the appointment of Rozanna Yaing as Senior Vice President, Quality and Regulatory Affairs, effective July 1, 2019. Ms. Yaing will be responsible for quality and regulatory affairs across Incysus’ portfolio and will serve on the Company’s Executive Committee.
“We are pleased that Ms. Yaing has joined Incysus at this exciting time. Her prior experience in cell and gene therapy, particularly her background including CAR-T immunotherapy, will be invaluable as we continue to advance our programs,” said William Ho, Chief Executive Officer of Incysus. “Additionally, her deep expertise in quality and regulatory strategies, coupled with her proven record of leading highly-effective cross-functional teams will be vitally important as we prepare to initiate human trials.”
Incysus has two Investigational New Drug applications (INDs) approved by the U.S. Food and Drug Administration (FDA) and expects to initiate Phase 1 clinical trials of its two lead programs this year. The first program is targeted for treatment of newly diagnosed glioblastoma, using Incysus’ Drug Resistant Immunotherapy (DRI) technology, and the second program is focused on treating leukemia and lymphoma patients undergoing stem cell transplantation with allogeneically delivered ?? T cells.
“Incysus represents a compelling opportunity to build its ?? T cell platform technology to target solid tumor cancers. The DRI approach, in combination with standard-of-care chemotherapy, has the potential to revolutionize the immunotherapy frontier,” said Ms. Yaing. “I am excited to join the Incysus team at this time to build a solid quality foundation and regulatory pathways in the development of Incysus’ product portfolio for the treatment of cancers.”
Ms. Yaing has more than 20 years of quality and regulatory experience, integrating strategies into drug development and medicine across multiple therapeutic areas. She joins Incysus from AxoGen Corporation, where she was Vice President of Quality. In that position, Ms. Yaing established quality and compliance strategies to realize sustainable growth and achieve BLA approval. Earlier in her career, Ms. Yaing held significant senior positions in Quality at Unum Therapeutics, Inc., uniQure, Inc., and Biocompass, Inc. Across her career, Ms. Yaing has played key roles in the development, scale-up and/or commercialization of products including, Glybera®, VPRIV®, Replagal®, Elaprase®, Cerezyme®, Taxus® Paclitaxel-Eluting Stents, and OP-1 Putty.
Ms. Yaing holds an MBA from the MIT Sloan School of Management, and a BS in Chemistry from Boston College.
About Incysus Therapeutics, Inc.
Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified gamma-delta (??) T cells, the Company’s technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers. Incysus’ immuno-oncology programs include activated and gene-modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. Since the Company’s inception in early 2016, Incysus has received approval of two Investigational New Drug applications (IND) and has initiated several cancer programs in early pre-clinical stages, including a checkpoint combination program. The Company’s first program is targeted to leukemia and lymphoma and its second program is targeted to the treatment of newly-diagnosed glioblastoma (GBM). In collaboration with our academic partners, including UAB, Incysus has advanced its technology and expects to begin both Phase 1 trials during 2019. For more information, visit www.incysus.com.
